Comparison of 30% salicylic acid with Jessner's solution for superficial chemical peeling in epidermal melasma.
OBJECTIVE
To compare the efficacy and safety of Jessner's solution with 30% salicylic acid as superficial chemical peeling agents in treating epidermal melasma in Asian skin.


METHODS
Double blind, randomized, interventional comparative study.


METHODS
Department of Dermatology, Combined Military Hospital, Malir Cantt, Karachi, from January to December 2004.


METHODS
Sixty consenting patients with epidermal melasma were randomly divided into two groups. Group A was treated with Jessner's solution and Group B with 30% salicylic acid. Baseline Melasma Area Severity Index (MASI) score was noted and peeling started at 2-weekly intervals. Sunscreen in morning and moisturizer at night were prescribed in all patients. MASI score and adverse effects were recorded biweekly. Treatment was stopped at 12 weeks and patients were followed-up at 4 weekly intervals for further 12 weeks. Final MASI score and adverse effects were noted at the end of follow-up period. Mean MASI scores were compared using paired sample t-test and one-way ANOVA.


RESULTS
Difference in baseline, treatment end and follow-up end MASI scores was not statistically significant between the two groups (p 0.54, 0.26, and 0.55 respectively). On the other hand, within group analysis of difference between pre and posttreatment MASI score was highly significant in both groups (p<0.0001). Adverse effects were mild and comparable in both groups.


CONCLUSIONS
Jessner's solution and 30% salicylic acid are equally effective and safe peeling agents for use in epidermal melasma in Asian skin.
Ejaz
Amer
A
Department of Dermatology, Combined Military Hospital, Kharian Cantonment. amer_ejaz@yahoo.com
Raza
Naeem
N
Iftikhar
Nadia
N
Muzzafar
Fawad
F
D000293:Adolescent; D000328:Adult; D044466:Asian People; D002615:Chemexfoliation / Q000379:methods*; D004311:Double-Blind Method; D004338:Drug Combinations; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use*; D019344:Lactic Acid / Q000627:therapeutic use*; D008297:Male; D008548:Melanosis / Q000628:therapy*; D012118:Resorcinols / Q000627:therapeutic use*; D012459:Salicylates / Q000627:therapeutic use*; D020156:Salicylic Acid / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D004338:Drug Combinations; C061170:Jessner's solution; D007641:Keratolytic Agents; D012118:Resorcinols; D012459:Salicylates; D019344:Lactic Acid; D000431:Ethanol; D020156:Salicylic Acid